JP2020516264A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516264A5 JP2020516264A5 JP2019555196A JP2019555196A JP2020516264A5 JP 2020516264 A5 JP2020516264 A5 JP 2020516264A5 JP 2019555196 A JP2019555196 A JP 2019555196A JP 2019555196 A JP2019555196 A JP 2019555196A JP 2020516264 A5 JP2020516264 A5 JP 2020516264A5
- Authority
- JP
- Japan
- Prior art keywords
- hbv
- immunogen
- viral vector
- expression cassette
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1705765.4 | 2017-04-10 | ||
| GBGB1705765.4A GB201705765D0 (en) | 2017-04-10 | 2017-04-10 | HBV vaccine |
| PCT/GB2018/050948 WO2018189522A1 (en) | 2017-04-10 | 2018-04-10 | Hbv vaccine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020516264A JP2020516264A (ja) | 2020-06-11 |
| JP2020516264A5 true JP2020516264A5 (enExample) | 2021-05-20 |
| JP7326157B2 JP7326157B2 (ja) | 2023-08-15 |
Family
ID=58744773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019555196A Active JP7326157B2 (ja) | 2017-04-10 | 2018-04-10 | Ｈｂｖワクチン |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20200113998A1 (enExample) |
| EP (1) | EP3609535B1 (enExample) |
| JP (1) | JP7326157B2 (enExample) |
| KR (1) | KR102700586B1 (enExample) |
| CN (2) | CN118576699A (enExample) |
| AU (1) | AU2018251241B2 (enExample) |
| CA (1) | CA3059290A1 (enExample) |
| DK (1) | DK3609535T3 (enExample) |
| ES (1) | ES3036962T3 (enExample) |
| GB (1) | GB201705765D0 (enExample) |
| MX (1) | MX2019012101A (enExample) |
| MY (1) | MY202396A (enExample) |
| PH (1) | PH12019502310A1 (enExample) |
| SG (1) | SG11201909353VA (enExample) |
| WO (1) | WO2018189522A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202091517A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и устройство для доставки вакцин против вируса гепатита b (hbv) |
| US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
| US11021692B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Hepatitis B virus (HBV) vaccines and uses thereof |
| WO2020178359A1 (en) * | 2019-03-05 | 2020-09-10 | Glaxosmithkline Biologicals Sa | Hepatitis b immunisation regimen and compositions |
| CA3143679A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai |
| CA3143632A1 (en) * | 2019-06-20 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof |
| PH12022550490A1 (en) * | 2019-08-29 | 2023-02-06 | Triad Nat Security Llc | Hepatitis b virus vaccines |
| KR20220074917A (ko) | 2019-09-30 | 2022-06-03 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 백신 및 hbv를 치료하는 방법 |
| WO2021243149A2 (en) * | 2020-05-28 | 2021-12-02 | President And Fellows Of Harvard College | Protein covariance networks reveal interactions important to the emergence of sars coronaviruses as human pathogens |
| IL299571A (en) * | 2020-07-08 | 2023-02-01 | Janssen Sciences Ireland Unlimited Co | Rna replicon vaccines against hbv |
| TW202229556A (zh) | 2020-10-02 | 2022-08-01 | 國立大學法人大阪大學 | 針對SARS-CoV-2之改良型DNA疫苗 |
| WO2022133230A1 (en) * | 2020-12-18 | 2022-06-23 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating hepatitis b virus infection |
| CN115595312A (zh) * | 2021-06-28 | 2023-01-13 | 中国农业大学（Cn） | 一种重组腺病毒及其应用 |
| US20250000968A1 (en) * | 2021-11-12 | 2025-01-02 | The United States of America, as represented by the Secretary,Department of Health and Human Service | Sars-cov-2 spike fused to a hepatitis b surface antigen |
| EP4444347A1 (en) | 2021-12-07 | 2024-10-16 | Barinthus Biotherapeutics (UK) Limited | Vaccine boost methods and compositions |
| CN121443308A (zh) * | 2023-03-17 | 2026-01-30 | 亥姆霍兹慕尼黑中心-德国健康与环境研究中心(有限公司) | 用于治疗乙型肝炎的hbv抗原制剂 |
| GB202317925D0 (en) | 2023-11-23 | 2024-01-10 | Spybiotech Ltd | Vaccines |
| CN118593695B (zh) * | 2024-08-07 | 2024-10-22 | 山东兴瑞生物科技有限公司 | 一种用于治疗HBV感染的siRNA和mRNA联合疫苗 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994012617A1 (en) | 1992-11-25 | 1994-06-09 | International Biotechnology Laboratories, Inc. | Hepatitis b virus vaccines |
| JP4644663B2 (ja) * | 2003-06-03 | 2011-03-02 | セル ジェネシス インコーポレイテッド | ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法 |
| EP2057268B1 (en) * | 2006-08-14 | 2014-08-13 | Postech Foundation | A dna vaccine for curing chronic hepatitis b and a method of preparing same |
| US10076570B2 (en) | 2009-08-07 | 2018-09-18 | Transgene S.A. | Composition for treating HBV infection |
| KR20120052352A (ko) | 2009-08-07 | 2012-05-23 | 트랜스진 에스.에이. | Ｈｂｖ 감염을 치료하는 조성물 |
| EP3266464A3 (en) | 2011-02-12 | 2018-03-14 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis b infection |
| TWI575070B (zh) * | 2011-07-12 | 2017-03-21 | 傳斯堅公司 | Ｈｂｖ聚合酶突變體 |
| CN103173492B (zh) * | 2013-03-12 | 2014-08-13 | 中国人民解放军白求恩国际和平医院 | 携带外源基因的复制型hbv载体、其转染后产生的重组hbv，和相应的制备方法与应用 |
| GB201321384D0 (en) * | 2013-12-04 | 2014-01-15 | Isis Innovation | Molecular adjuvant |
-
2017
- 2017-04-10 GB GBGB1705765.4A patent/GB201705765D0/en not_active Ceased
-
2018
- 2018-04-10 US US16/604,221 patent/US20200113998A1/en not_active Abandoned
- 2018-04-10 SG SG11201909353V patent/SG11201909353VA/en unknown
- 2018-04-10 CN CN202410387306.0A patent/CN118576699A/zh active Pending
- 2018-04-10 WO PCT/GB2018/050948 patent/WO2018189522A1/en not_active Ceased
- 2018-04-10 AU AU2018251241A patent/AU2018251241B2/en active Active
- 2018-04-10 MY MYPI2019005911A patent/MY202396A/en unknown
- 2018-04-10 JP JP2019555196A patent/JP7326157B2/ja active Active
- 2018-04-10 EP EP18719248.9A patent/EP3609535B1/en active Active
- 2018-04-10 MX MX2019012101A patent/MX2019012101A/es unknown
- 2018-04-10 KR KR1020197031896A patent/KR102700586B1/ko active Active
- 2018-04-10 CA CA3059290A patent/CA3059290A1/en active Pending
- 2018-04-10 CN CN201880028408.6A patent/CN110913899B/zh active Active
- 2018-04-10 ES ES18719248T patent/ES3036962T3/es active Active
- 2018-04-10 DK DK18719248.9T patent/DK3609535T3/da active
-
2019
- 2019-10-08 PH PH12019502310A patent/PH12019502310A1/en unknown
-
2023
- 2023-06-06 US US18/206,249 patent/US12521431B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516264A5 (enExample) | ||
| JP7326157B2 (ja) | Ｈｂｖワクチン | |
| CN1180843C (zh) | 多表位疫苗 | |
| JP6702725B2 (ja) | 改良されたポックスウイルスワクチン | |
| EP2408473B1 (en) | Vaccination methods | |
| KR20180100228A (ko) | Hbv를 치료하기 위한 수단 및 방법 | |
| JP2014507146A5 (enExample) | ||
| JP2005523318A5 (enExample) | ||
| JP2016510989A5 (enExample) | ||
| JP2020536489A5 (enExample) | ||
| JP2003511010A (ja) | ヒト細胞中での発現用に最適化された合成ヒトパピローマウイルス遺伝子 | |
| CA2683679A1 (en) | Adenoviral vector encoding malaria antigen | |
| EP2391383B1 (en) | Codon-optimized hepatitis b virus core antigen (hbcag) | |
| US20190083607A1 (en) | Chimeric hepatitis d virus antigen and hepatitis b virus pre s1 genes for use alone or in vaccines contaning hepatitis b virus genes | |
| RU2018122755A (ru) | Слитые белки fmdv-e2 и их применение | |
| WO2007119279A1 (ja) | コイヘルペスウイルス（ｋｈｖ）病用ｄｎａワクチン | |
| CN111741766A (zh) | 用于诱导针对乙型肝炎病毒(hbv)的免疫应答的方法和组合物 | |
| JP2023528984A (ja) | コロナウイルス病に対する組換え修飾ワクシニアウイルスアンカラ（ｍｖａ）ワクチン | |
| AU2013339846B2 (en) | Chimeric vaccine antigens against hepatitis C virus | |
| KR101863335B1 (ko) | 어류 바이러스성 출혈성 패혈증에 대한 예방 또는 치료용 dna 백신 | |
| CN102000330B (zh) | 一种核酸疫苗佐剂及其构建方法 | |
| JP2013512256A5 (enExample) | ||
| Basirnejad et al. | Development of HCV therapeutic vaccines using Hp91 peptide and small heat shock protein 20 as an adjuvant | |
| JPWO2020065349A5 (enExample) | ||
| CN102276725B (zh) | 隐孢子虫CTL和Th混合多表位基因和融合蛋白及应用 |